ArticleScientific reports2025
Cucurbitacin B suppresses glioblastoma via the STAT3/ROS/endoplasmic reticulum stress pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cucurbitacin B (CuB), the tetracyclic triterpenoid compound belonging to cucurbitaceae family, demonstrates significant anticancer properties across various tumor types. However, its efficacy against glioblastoma (GBM), particularly in overcoming blood-brain barrier (BBB) and unique tumor microenvironment, remains a critical area of investigation. Our study reveals that CuB causes GBM cell apoptosis via STAT3/ROS/endoplasmic reticulum (ER) stress pathway. To enhance targeted delivery, we developed M@CuB-Lips, a novel formulation of CuB encapsulated in cancer cell membrane-coated liposomes. In vitro and in vivo experimental results verified targeted M@CuB-Lips delivery to brain tumor sites, demonstrating significant tumor inhibition and enhanced effector T-cell infiltration. These findings underscore CuB's potential in GBM therapy, particularly through STAT3 suppression and ROS-ER Stress pathway activation, while M@CuB-Lips offers a promising strategy for targeted drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.